Drug intelligence / Profile preview

desmethylarzoxifen

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

Desmethylarzoxifen (also known as LY335562 or DMA) is a selective estrogen receptor modulator (SERM) and the primary active metabolite of arzoxifen (LY353381), which was originally developed by Eli Lilly. It binds to the estrogen receptor (ER) with high affinity and acts as an antagonist, inhibiting estrogen-dependent cell proliferation. In addition to its ER-mediated effects, desmethylarzoxifen has been shown to possess chemopreventive activity by attenuating oxidative estrogen metabolism and reducing the formation of genotoxic catechol estrogens and reactive oxygen species in breast epithelial cells.

Other names: DMAO-desmethylarzoxifenO-desmethylarzoxifenedesmethyl-arzoxifendesmethylarzoxifene

Targets

ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on desmethylarzoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on desmethylarzoxifen.

Explore the full profile